NCT00384735 (TOSS) is a clinical trial in Sarcoma, sponsored by Terry Fox Foundation.

Who is sponsoring NCT00384735?

NCT00384735 is sponsored by Terry Fox Foundation.

Is NCT00384735 still recruiting?

NCT00384735 is currently completed. Last updated 8 October 2020.

Last reviewed 2020-10-08 · How we verify

NCT00384735: TOSS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized Trial

Completed Last updated 8 October 2020

What this trial tests

trial in Sarcoma in 500 participants. Completed in 31 December 2015.

Timeline

1 January 2006

Primary endpoint
30 June 2010

31 December 2015

Quick facts

Lead sponsor	Terry Fox Foundation
Status	Completed
Study type	OBSERVATIONAL
Enrollment	500
Start date	1 January 2006
Primary completion	30 June 2010
Estimated completion	31 December 2015
Sites	1 location across India

Conditions studied

Sarcoma — all drugs for Sarcoma →

Sponsor

Terry Fox Foundation

Who can join

Adults 1 to 65, any sex, with Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the impact on overall survival of an intensive follow-up protocol (as practiced today at TMH) against a more cost effective follow-up protocol in patients operated for extremity sarcoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Sarcoma

Currently open trials in the same condition.

NCT07402577 — Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot · recruiting
NCT07501026 — Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC) · Phase 2 · recruiting
NCT07359911 — Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patient · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00384735 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Terry Fox Foundation
Last refreshed: 8 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00384735.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing